The ASX is packed with revolutionary companies taking it to the next step for the betterment of their shareholders and their own bottom line. These three players are flying at 52-week highs, as their share prices soar off the back of overall innovation and expertise.
Bravura Solutions Ltd (ASX: BVS)
Emerging software company Bravura Solutions Ltd is gaining notoriety in the fintech space for providing its clients in the wealth management sector with revolutionary products to manage their systems.
Demand for Bravura’s products has been growing strongly, especially its Sonata administration solutions product which now accounts for 55% of Bravura’s overall revenue.
Bravura’s share price has rocketed up from $1.36 at this time last year to $3.14 at the time of writing, up 2.9%.
One to watch, as while Bravura currently sits on a market cap of $653 million it screams blue chip potential from all fronts.
Future Generation Global Invstmnt Co Ltd (ASX: FGX)
If you’ve been looking for a share to buy your grandkids Future Generation Global Invstmnt Co Ltd should be top of the list, in my opinion.
This philanthropically-focused small cap provides its investors with diversified exposure to Australian equities and makes a financial contribution to Australian children’s charities with part of its proceeds.
Stocks like Future Generation are considered alternative investment options by many, but it was founded by one of Australia’s most well-known successful investors, Geoff Wilson, and it’s the safest way I can think of for Aussie investors to gain exposure to investment strategies and options that would otherwise be out of their reach.
The Future Generation share price is currently at a 52-week high after jumping up from $1.12 at this time last year to $1.21 at the time of writing.
If you’re not sure if it’s the right time to buy into Future Generation at least keep it on your watch list – it looks to have big things in store.
Cochlear Limited (ASX: COH)
A manufacturer and distributor of implantable hearing devices across 20 countries, Cochlear Limited, shares are flying at a 52-week high as the company appears to go from strength-to-strength.
Cochlear shares were at $197.90 at the time of writing – up from $141.52 at this time last year and while many investors consider this too expensive to jump on for a buy in, others appear to be backing this company no matter what, such is the belief that Cochlear’s future is unfalteringly lucrative.
And Cochlear is not the only outperformer still managing to net new gains, with peer CSL Limited (ASX: CSL), currently sitting at a high of $171.48. It continues to make the grade for brokers like UBS who have a buy on the stock and a price target of $175.
If these two stocks still seem too expensive for you, why not cast your eyes over the likes of Sonic Healthcare Limited (ASX: SHL) which is in the midst of asserting itself on a global scale as its operations in Germany and the US strengthen and its pathology arm gains global traction.
On the topic of disruptors, check out these 3 Revolutionary Aussie Companies to Back for 2018
We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.
That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Cochlear or REA Group.
We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!
Motley Fool contributor Carin Pickworth has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of Bravura Solutions Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.